THE US Food and Drug
Administration has approved
Cometriq (cabozantinib) to treat
medullary thyroid cancer that has
spread to other parts of the body
(metastasised).
Cometriq is a kinase inhibitor that
blocks abnormal kinase proteins
involved in the development and
growth of medullary cancer cells.
Patients should not eat for at
least 2 hours before and 1 hour
after taking Cometriq.
See www.fda.gov.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Dec 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Dec 12
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.